Gyre Therapeutics, Inc.
General ticker "GYRE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $709.7M (TTM average)
Gyre Therapeutics, Inc. follows the US Stock Market performance with the rate: 0.8%.
Estimated limits based on current volatility of 2.6%: low 5.91$, high 6.22$
Factors to consider:
- Total employees count: 5 as of 2024
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.81$, 9.58$]
- 2026-12-31 to 2027-12-31 estimated range: [3.98$, 9.70$]
Financial Metrics affecting the GYRE estimates:
- Positive: with PPE of 48.0 at the end of fiscal year the price was low
- Positive: 7.60 < Operating profit margin, % of 9.85
- Positive: 1.85 < Return on assets ratio (scaled to [-100,100]) of 5.61
- Negative: negative Industry operating cash flow (median)
- Negative: Inventory ratio change, % of 2.49 > 0.80
- Negative: Industry earnings per price (median), % of -12.76 <= 0
- Negative: 42.58 < Shareholder equity ratio, % of 63.82 <= 64.15
Short-term GYRE quotes
Long-term GYRE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $110.11MM | $105.69MM | $116.58MM |
| Operating Expenses | $177.34MM | $89.53MM | $105.10MM |
| Operating Income | $-67.23MM | $16.16MM | $11.49MM |
| Non-Operating Income | $-9.73MM | $7.05MM | $2.95MM |
| R&D Expense | $96.88MM | $12.02MM | $13.70MM |
| Income(Loss) | $-76.97MM | $23.22MM | $14.44MM |
| Taxes | $8.52MM | $5.32MM | $4.56MM |
| Profit(Loss)* | $-92.93MM | $12.09MM | $5.03MM |
| Stockholders Equity | $-15.83MM | $63.32MM | $106.03MM |
| Inventory | $4.28MM | $6.34MM | $10.17MM |
| Assets | $116.54MM | $125.41MM | $166.13MM |
| Operating Cash Flow | $25.89MM | $-3.64MM | $1.01MM |
| Capital expenditure | $8.59MM | $3.13MM | $1.19MM |
| Investing Cash Flow | $-19.76MM | $-19.88MM | $-0.47MM |
| Financing Cash Flow | $2.50MM | $2.10MM | $24.38MM |
| Earnings Per Share** | $-1.41 | $0.14 | $0.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.